Inside Phantom Neuro's First Human Implants: Sensing Muscle Beneath the Skin
Dr. Dereck Mush, MD, MBA
Vitroscope
Live human tissue perfusion platforms for drug discovery and experimental research.
What they do
Vitroscope develops perfusion platforms with real-time control of oxygen, pH and temperature plus live-cell imaging. Its vitro.alive benchtop platform runs six independent parallel experiments on standard inverted microscopes. On November 3, 2026 it announced $7 million in combined funding: $5 million seed and $2 million non-dilutive funding. The company reports $8.8 million raised to date. Its vitro.scale platform is in development for 96 parallel experiments, with customer testing expected in 2027 and launch planned in 2028. Carlo Kriesi is co-founder and CEO.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Live human tissue perfusion
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- Not disclosed
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- $8.8M raised
Notable investors: Cerberus Ventures, YZR Capital, Arcas Ventures, Golden Egg Check, Devico Invest.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA